FBRX
NASDAQForte Biosciences Inc.
News · 26 weeks85+236%
2026-03-082026-08-30
Mix5890d
- SEC Filings22(38%)
- Other18(31%)
- Insider13(22%)
- Earnings3(5%)
- Analyst1(2%)
- M&A1(2%)
Latest news
25 items- SECSEC Form POS AM filed by Forte Biosciences Inc.POS AM - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form POS AM filed by Forte Biosciences Inc.POS AM - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form POS AM filed by Forte Biosciences Inc.POS AM - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form POS AM filed by Forte Biosciences Inc.POS AM - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form POS AM filed by Forte Biosciences Inc.POS AM - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form POS AM filed by Forte Biosciences Inc.POS AM - Forte Biosciences, Inc. (0001419041) (Filer)
- INSIDERDirector Kornfeld Steven closing all direct ownership in the company (SEC Form 4) to cover withholding tax4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Brun Scott C. to cover withholding tax4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERDirector Gryska David W closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Vincent Richard G to satisfy withholding tax4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Finck Barbara K (withholding obligation)4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Kapoor Shivpreet Singh to cover taxes4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Doberstein Stephen K to cover taxes4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Riley Antony A closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- SECSEC Form S-8 POS filed by Forte Biosciences Inc.S-8 POS - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form S-8 POS filed by Forte Biosciences Inc.S-8 POS - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form S-8 POS filed by Forte Biosciences Inc.S-8 POS - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form S-8 POS filed by Forte Biosciences Inc.S-8 POS - Forte Biosciences, Inc. (0001419041) (Filer)
- INSIDEROfficer Wagner Paul A. closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- SECSEC Form S-8 POS filed by Forte Biosciences Inc.S-8 POS - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form S-8 POS filed by Forte Biosciences Inc.S-8 POS - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form S-8 POS filed by Forte Biosciences Inc.S-8 POS - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form S-8 POS filed by Forte Biosciences Inc.S-8 POS - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form S-8 POS filed by Forte Biosciences Inc.S-8 POS - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form S-8 POS filed by Forte Biosciences Inc.S-8 POS - Forte Biosciences, Inc. (0001419041) (Filer)
FBRX FAQ
7 questionsWhat does Forte Biosciences Inc. do?
Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.Where does FBRX stock trade?
Forte Biosciences Inc. (FBRX) is listed on NASDAQ.What sector and industry is FBRX in?
Forte Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Forte Biosciences Inc. go public?
Forte Biosciences Inc. (FBRX) completed its IPO in 2017.What are analysts saying about FBRX?
Forte Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-07-21. Recent price targets range from $275.00 to $350.00.What companies are similar to FBRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare FBRX side-by-side with any of them on Quantisnow.How can I track FBRX on Quantisnow?
Quantisnow aggregates Forte Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FBRX to receive live email and push alerts on every new disclosure.